AAV virions with decreased immunoreactivity and uses therefor

Details AAV virions with decreased immunoreactivity and uses therefor AAV virions with decreased immunoreactivity and uses therefor

2007-08-21

2007-08-21

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093200, C424S233100

Reexamination Certificate

active

10873632

ABSTRACT:
Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.

REFERENCES:
patent: 6733757 (2004-05-01), Patel et al.
patent: 2002/0192823 (2002-12-01), Bartlett
patent: 2003/0053990 (2003-03-01), Rabinowitz et al.
Wu, et al. Mutational analysis of the Adeno-associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism:, Journal of Virology, 74(18):8635-8647 (2000).
Arbetman et al.; “Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.I) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties,” Journal of virology, 79(24):15238-15245 (2005).
Lochrie et al., “Mutations on the External Surfaces of Adeno-Associated Virus Type 2 Capsids That Effect Transduction and Neutralization,” Journal of virology, 80(2):821-834 (2006).
Wu et al., “Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors With Altered Tropism,” Journal of virology, 74(18):8635-8647 (2000).
Gao et al., “Novel Adeno-Associated Viruses From Rhesus Monkeys as Vectors for Human Gene Therapy”,PNAS, 99(18):11854-11859 (2002).
Halbert et al., “Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression During the Initial Exposure”,J. Virol., 72(12):9795-9805 (1998).
Huttner et al., “Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce the Affinity and the Neutralizing Effects of Human Serum Antibodies”,Gene Therapy, 10:2139-2147 (2003).
Moskalenko et al., “Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure”,J. Virol., 74(4):1761-1766 (2000).
Opie et al., “Identification of Amino Acid Residues in the Capsid Proteins of Adeno-Associated Virus Type 2 That Contribute to Heparan Sulfate Proteoglycan Binding”,J. Virol., 77(12):6995-7006 (2003).
Schmidt et al., “Cloning and Characterization of a Bovine Adeno-Associated Virus”,J. Virol., 78(12):6509-6516 (2004).
Lochrie, et al., “Mutation of 53 Amino Acids on the Surface of Adeno-Associated Virus Type-2.”Molecular TherapyMay 2003, vol.7, No.5, part 2, p. S40, Abstract No. 100.
Lochrie, et al., Effect of 127 Mutations at 72 positions on the surface of adeno-associated virus type-2.Molecular TherapyMay 2004, vol. 9, Supplement 1, p. S286, Abstract No. 752.

Affiliated with

Also associated with

Rating

AAV virions with decreased immunoreactivity and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with AAV virions with decreased immunoreactivity and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and AAV virions with decreased immunoreactivity and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3854067